Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice
AP Mitchell, MR Harrison, MS Walker… - Journal of oncology …, 2015 - ascopubs.org
Purpose: Although narrow eligibility criteria improve the internal validity of clinical trials, they
may result in differences between study populations and real-world patients, threatening …
may result in differences between study populations and real-world patients, threatening …
Assessing the value of patient-generated data to comparative effectiveness research
L Howie, B Hirsch, T Locklear, AP Abernethy - Health Affairs, 2014 - healthaffairs.org
The goal of comparative effectiveness research is to assess medical therapies and allow
patients, health care providers, payers, and policy makers to make evidence-based …
patients, health care providers, payers, and policy makers to make evidence-based …
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy
SM Rittig, M Haentschel, KJ Weimer, A Heine… - …, 2016 - Taylor & Francis
Renal cell carcinoma (RCC) is an immunogenic tumor for which immunotherapeutic
approaches could be associated with clinically relevant responses. It was recently shown …
approaches could be associated with clinically relevant responses. It was recently shown …
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
S Pal, J Gong, SK Mhatre, SW Lin, A Surinach, S Ogale… - BMC cancer, 2019 - Springer
Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and
mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) …
mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) …
[HTML][HTML] The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians
J Jones, J Bhatt, J Avery, A Laupacis… - Canadian Urological …, 2017 - ncbi.nlm.nih.gov
It is critically important to define disease-specific research priorities to better allocate limited
resources. There is growing recognition of the value of involving patients and caregivers, as …
resources. There is growing recognition of the value of involving patients and caregivers, as …
Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States
Background To evaluate the evolution of treatment patterns and associated costs for
metastatic renal cell carcinoma (mRCC) in the United States. Materials and Methods The …
metastatic renal cell carcinoma (mRCC) in the United States. Materials and Methods The …
[HTML][HTML] Changes in treatment reality and survival of patients with advanced clear cell renal cell carcinoma–analyses from the german clinical RCC-registry
PJ Goebell, M Staehler, L Müller, A Nusch… - Clinical Genitourinary …, 2018 - Elsevier
Introduction Because the treatment landscape for metastatic renal cell carcinoma (mRCC)
has evolved dramatically over the past decade, data on patients' treatment and outcomes in …
has evolved dramatically over the past decade, data on patients' treatment and outcomes in …
A decision analysis evaluating screening for kidney cancer using focused renal ultrasound
SH Rossi, T Klatte, JA Usher-Smith, K Fife… - European Urology …, 2021 - Elsevier
Background Screening for renal cell carcinoma (RCC) has been identified as a key research
priority; however, no randomised control trials have been performed. Value of information …
priority; however, no randomised control trials have been performed. Value of information …
Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: update of the RENCOMP study with subgroup analysis of the …
M Lindskog, T Wahlgren, R Sandin, J Kowalski… - … Oncology: Seminars and …, 2017 - Elsevier
Background This retrospective study investigated overall survival (OS) and factors
influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the …
influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the …
Exposure to multiple lines of treatment and survival of patients with metastatic renal cell carcinoma: a real-world analysis
R Ratta, E Verzoni, M Di Maio, P Grassi… - Clinical genitourinary …, 2018 - Elsevier
Background The purpose of the present retrospective analysis was to describe the trends in
exposure to multiple lines of treatment and overall survival (OS) in patients with metastatic …
exposure to multiple lines of treatment and overall survival (OS) in patients with metastatic …